Dual <scp>PD</scp> ‐1 and <scp>CTLA4</scp> Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers
Nivolumab/ipilimumab and palliative XRT result in low rates of severe toxicities and modest response rates for SGC; further work is necessary to explore predictors for response.
Authors
- Brittany Barber
- Neal Futran
- Diane Tseng
- George E. Laramore (ORCID: https://orcid.org/0000-0003-2595-2123)
- Jonathan R. Fromm (ORCID: https://orcid.org/0000-0002-2287-5284)
- Qian Wu (ORCID: https://orcid.org/0000-0002-2292-4816)
- Sylvia M. Lee
- Jay J. Liao (ORCID: https://orcid.org/0000-0003-4679-3037)
- Kevin Ng
- Simon S. Lo (ORCID: https://orcid.org/0000-0002-3744-4065)
- Jenna Voutsinas (ORCID: https://orcid.org/0000-0002-7474-4892)
- Christina S. Baik (ORCID: https://orcid.org/0009-0007-0822-9060)
- Keith D. Eaton (ORCID: https://orcid.org/0000-0001-5025-2001)
- Emily Marchiano
- Upendra Parvathaneni (ORCID: https://orcid.org/0000-0003-2370-4492)
- Rafael Santana-Dávila (ORCID: https://orcid.org/0000-0001-5051-1755)
- Ariana Dumenigo‐Jimenez
- Cristina P. Rodriguez (ORCID: https://orcid.org/0000-0003-3568-2630)
- Renato Martins (ORCID: https://orcid.org/0000-0003-2137-1145)
Institutions
- Virginia Commonwealth University (US)
- University of Washington (US)
- Fred Hutch Cancer Center (US)
Publication Details
- Journal
- Head & Neck
- Published
- 2025-04-24
- DOI
- https://doi.org/10.1002/hed.28169
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb